Advertisement
 

Amgen gets bad news in drug study

April 17, 2007|From Bloomberg News

One in 4 cancer patients given Amgen Inc.'s Aranesp anemia drug in a study died after 19 weeks, a rate about 5 percentage points higher than among those on a placebo, a finding likely to make doctors more cautious about the product.

Researchers released new details Monday about the study of 851 cancer patients. The mortality rate was 49% after two years, compared with 46% for the placebo, the scientists said in Los Angeles. The drug failed to reach the goal of reducing blood transfusions, according to the report.

Aranesp is already the world's top-selling drug to treat anemia. The trial, however, may prevent Thousand Oaks-based Amgen from winning U.S. approval to market the product for use by cancer patients who are not receiving chemotherapy, as distinct from those with anemia induced by such treatment.

Advertisement
Los Angeles Times Articles
|
|
|